En español
NIDA

Search

Menu

Office of the DPMCDA Director (OD)

What We Do:

Provides leadership and direction to the varied activities of the Division’s programs. He is assisted in this endeavor by staff who coordinate the functional areas of the OD, DPMCDA. The Informatics Unit, residing in the OD, DPMCDA, designs, develops, integrates, supports, and provides information technology tools, customized applications, informatics support, bio-informatics programs, and support for scientific computing. The functional areas within the OD, DPMCDA provide policy and technology transfer guidance, program development and evaluation, and overall operational, administrative, and budgeting coordination for the Division. The OD, DPMCDA works closely with the OD, NIDA in establishing relationships with other Government agencies and health organizations, Congress, academia, and the private sector.

Staff Biographies and Research Interests:

  • Phil Skolnick, Ph.D., D.Sc. (hon.), - Director
    301-443-6173
    Provides leadership, programmatic oversight, and direction for all DPMCDA activities. Manages resources involved in the development of immunological and pharmacological approaches for the treatment of nicotine, stimulant (cocaine, methamphetamine), opioid, and cannabis dependence disorders. Served as Senior Investigator and Chief, Laboratory of Neuroscience, NIDDK, NIH (1986-1997), Lilly Research Fellow in Neuroscience, Lilly Research Laboratories (1997-2001), and Chief Scientific Officer, DOV Pharmaceutical, Inc. (2001-2009). Joined DPMCDA in January of 2010.
  • Ivan Montoya, M.P.H., M.D., - Deputy Director
    301-443-8639
    Dr. Montoya is a psychiatrist and epidemiologist who specialize in the public health aspects and the development of medications for the treatment of substance-related disorders (SRDs). In conjunction with the Division Director, he provides programmatic oversight for grants and contracts in DPMCDA, and manages activities and resources of the Division involved in the development of medications for the treatment of SRDs. He also serves as Medical Monitor and provides medical oversight to grants and contracts, as well as supports NIDA’s implementation of NIH wide policies for data and safety monitoring of clinical trials. He leads NIDA’s marijuana medications development iniative. He collaborates with the IRP in research projects,  with the NIDA’s International Office in the Latin American Initiative, and is member of several scientific interest workgroups. Previous experience includes seven years as a clinical investigator in the Intramural Research Program of NIDA, and four years in academia. He joined NIDA in December 1999.
  • David J. McCann. Ph.D., - Associate Director
    301-443-2999
    Provides leadership, programmatic oversight, and direction for all DPMCDA projects. Manages resources involved in the development of immunological and pharmacological approaches for the treatment of psychoactive substance disorders, with an emphasis on cocaine, methamphetamine and cannabis dependence disorders. Received a B.S. in Pharmacy from the Albany College of Pharmacy in 1981 and his Ph.D. from the Department of Pharmacology and Therapeutics, SUNY Buffalo in 1988. After serving as a Staff Fellow and then a Senior Staff Fellow at the NIDA Intramural Research Program, joined the Medications Development Program in 1992.
  • Aida M. Klun, M.B.A., - Program Analyst
    301-443-1122
    Plans, coordinates, and executes the administrative and managerial aspects of the Division. Assists the Director, DPMCDA with special research and analysis projects, personnel management, project management and strategic planning, procurement, space and property management, special events, presentations, special projects, operations and clinical trial budgets, technology transfer and other business-related interactions with private industry and academia, in support of divisional planning and evaluation activities. Joined DPMCDA in 1997.
  • Donna Inman, B.S., - Program Analyst
    301-443-1078
    Coordinates and monitors the Division’s contract portfolio.  Ensures budget spending compliance of non-clinical and clinical contracts by analyzing, developing, and implementing tracking mechanisms, computing budget projections, and monitoring timelines. Works closely with FMB to ensure all funds are obligated in a timely manner. 14 years of budget analysis (West Los Angeles VA) and 3.5 years as a NIDA contractor. Joined DPMCDA in 2000.

This page was last updated December 2011

    Featured Publication

    Featured Publication

    Drugs, Brains, and Behavior - The Science of Addiction

    As a result of scientific research, we know that addiction is a disease that affects both brain and behavior.